CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

CNS Pharmaceuticals (NASDAQ:CNSP) participated in a Virtual Investor "What This Means" segment where CFO Steve O'Loughlin discussed the Company's recently completed oversubscribed $22.5 million financing.

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ:CNSP) participated in a Virtual Investor "What This Means" segment where CFO Steve O'Loughlin discussed the Company's recently completed oversubscribed $22.5 million financing. Topics included the strategic reset, acquisition-focused transformation, institutional investor participation, investor reception, balance sheet strength and long-term growth and shareholder value objectives.

Positive

• Oversubscribed $22.5 million financing recently completed
• Participation from leading healthcare-focused institutional investors
• Financing follows a strategic reset and acquisition-focused transformation
• Stronger balance sheet to pursue potential transformational opportunities
• Management publicly articulated long-term vision for creating shareholder value

Negative

• None.

Argus Jun 8 session

-2.20% close to close Open Argus

Details

News Market Reaction – CNSP

On Jun 8, the day this news came out, CNSP closed 2.20% below the previous close.

Data tracked by StockTitan Argus for the Jun 8 session.

Key Figures

Financing amount: $22.5 million

Financing amount

$22.5 million

Recently completed oversubscribed financing discussed in Virtual Investor segment

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   Q1 earnings update

   24h Move

   -9.2%

   Reported higher expenses and net loss while detailing strategic transformation progress.

2. May 04

   Private placement

   24h Move

   +239.2%

   Announced oversubscribed $22.5M private placement with institutional investors and warrants.

3. Mar 11

   Strategy pivot

   24h Move

   -11.6%

   Launched new corporate strategy to build neurology and oncology pipeline via acquisitions.

4. Mar 02

   CMO appointment

   24h Move

   +0.6%

   Named experienced CMO to lead clinical development and regulatory strategy.

5. Feb 17

   Executive hires

   24h Move

   -5.8%

   Recruited new CFO, CTO and CBO to drive strategic transformation and execution.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Access the segment here

HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.

Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation. The conversation explored investor reception to the Company's evolving strategy, the significance of participation from leading healthcare-focused institutional investors and how the strengthened balance sheet enhances CNS Pharmaceuticals' ability to pursue potential transformational opportunities. Mr. O'Loughlin also discussed the importance of institutional support and the Company's long-term vision for creating shareholder value as it advances its next phase of growth.

The Virtual Investor "What This Means" segment is available for on-demand viewing here.

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

Business Development Contact
CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financing did CNS Pharmaceuticals (NASDAQ:CNSP) discuss in the June 8, 2026 Virtual Investor segment?

CNS Pharmaceuticals discussed its recently completed oversubscribed $22.5 million financing. According to CNS Pharmaceuticals, the conversation covered factors behind the capital raise and how the enhanced balance sheet supports pursuing potential transformational opportunities and the company’s long-term growth plans.

How does the $22.5M financing impact CNS Pharmaceuticals' balance sheet and growth strategy (CNSP)?

The $22.5 million financing is described as strengthening CNS Pharmaceuticals’ balance sheet. According to CNS Pharmaceuticals, this improved financial position supports its acquisition-focused transformation and ability to pursue potential transformational opportunities in line with its next phase of growth and shareholder value goals.

What role did institutional investors play in CNS Pharmaceuticals' recent $22.5M financing (CNSP)?

Leading healthcare-focused institutional investors participated in the $22.5 million financing. According to CNS Pharmaceuticals, the Virtual Investor segment highlighted the significance of this institutional support and investor reception to the company’s evolving strategy and acquisition-focused transformation after its strategic reset.

What strategic changes at CNS Pharmaceuticals were discussed alongside the $22.5M financing (CNSP)?

CNS Pharmaceuticals’ CFO discussed a strategic reset and an acquisition-focused transformation. According to CNS Pharmaceuticals, the Virtual Investor segment linked these strategic changes with the successful oversubscribed $22.5 million financing and the company’s vision for long-term growth and creating shareholder value.

Where can investors watch CNS Pharmaceuticals' June 2026 Virtual Investor "What This Means" segment about CNSP?

The Virtual Investor "What This Means" segment is available for on-demand viewing online. According to CNS Pharmaceuticals, the recording features CFO Steve O'Loughlin discussing the oversubscribed $22.5 million financing, institutional investor participation and the company’s evolving growth and acquisition-focused strategy.